CLAIMS

1. A method for treating a subject with occult brain metastasis comprising administering to said subject a composition comprising an immunomodulatory polypeptide and a baculovirus-insect cell preparation.

2. The method of claim 1, wherein the composition is injected directly into a tumor or into tumor vasculature not located in the brain.

3. The method of claim 1, wherein said immunomodulatory polypeptide was expressed from a recombinant baculovirus vector in an insect cell.

4. The method of claim 1, wherein the immunomodulatory polypeptide is IFN-α, IFN-β, IFN-γ, IL-1, IL-2, IL-6, IL-7, IL-12, IL-15, IL-16 or GM-CSF.

5. The method of claim 1, wherein the composition further comprises an inflammatory stimulus.

6. The method of claim 5, wherein the inflammatory stimulus is whole bacteria, endotoxin, or unmethylated DNA.

7. The method of claim 1, wherein said composition comprises *Spodoptera* or *Trichoplusia* cells.

8. The method of claim 1, further comprising a second administration of said composition.

9. The method of claim 8, further comprising a third administration of said composition.

10. The method of claim 1, wherein said composition comprises between about 10^5 and about 10^7 insect cells.

11. The method of claim 10, wherein said composition comprises intact insect cells.

12. The method of claim 10, wherein said composition comprises disrupted insect cells.

13. The method of claim 1, wherein said composition is lyophilized.

14. The method of claim 12, wherein said composition has been freeze/thawed.

15. The method of claim 1, wherein the occult brain metastasis is derived from a primary tumor in said subject's bone, liver, spleen, pancreas, lung, colon, testis, ovary, breast, cervix, prostate, and uterus.

16. The method of claim 1, wherein said composition further comprises a tumor antigen.

17. The method of claim 16, wherein said tumor antigen is MAGE-1, MAGE-3, Melan-A, P198, P1A, gp100, TAG-72, $p185^{HER2}$, milk mucin core protein, carcinoembryonic antigen (CEA), P91A, p53, $p21^{ras}$, P210, BTA or tyrosinase.

18. The method of claim 17, wherein said tumor antigen was expressed from a recombinant baculovirus vector in an insect cell.

19. The method of claim 1, wherein said subject is a human subject.

20. The method of claim 1, further comprising a second anti-cancer therapy.

21. The method of claim 20, wherein said second anti-cancer therapy is radiotherapy, chemotherapy, gene therapy or surgery.

22. The method of claim 1, wherein said subject has previously received cancer therapy.

23. A method for preventing the development of occult brain metastasis in a subject comprising administering to said subject a composition comprising an immunomodulatory polypeptide and a baculovirus-insect cell preparation.

24. A method for treating a subject with occult brain metastasis comprising administering to said subject a composition comprising an immunomodulatory polypeptide and an inflammatory stimulus.

25. The method of claim 24, wherein the composition is injected directly into a tumor or into tumor vasculature not located in the brain.

26. The method of claim 24, wherein said immunomodulatory polypeptide was expressed from a recombinant baculovirus vector in an insect cell.

27. The method of claim 24, wherein the immunomodulatory polypeptide is IFN-α, IFN-β, IFN-γ, IL-1, IL-2, IL-6, IL-7, IL-12, IL-15, IL-16 or GM-CSF.

28. The method of claim 24, wherein the inflammatory stimulus is whole bacteria, endotoxin, or unmethylated DNA.

29. The method of claim 24, wherein said composition comprises *Spodoptera* or *Trichoplusia* cells.

30. The method of claim 24, further comprising a second administration of said composition.

31. The method of claim 30, further comprising a third administration of said composition.

32. The method of claim 24, wherein said composition is lyophilized.

33. The method of claim 24, wherein said composition has been freeze/thawed.

34. The method of claim 24, wherein the occult brain metastasis is derived from a primary tumor in said subject's bone, liver, spleen, pancreas, lung, colon, testis, ovary, breast, cervix, prostate, and uterus.

35. The method of claim 24, wherein said composition further comprises a tumor antigen.

36. The method of claim 35, wherein said tumor antigen is MAGE-1, MAGE-3, Melan-A, P198, P1A, gp100, TAG-72, $p185^{HER2}$, milk mucin core protein, carcinoembryonic antigen (CEA), P91A, p53, $p21^{ras}$, P210, BTA or tyrosinase.

37. The method of claim 36, wherein said tumor antigen was expressed from a recombinant baculovirus vector in an insect cell.

38. The method of claim 24, wherein said subject is a human subject.

39. The method of claim 24, further comprising a second anti-cancer therapy.

40. The method of claim 39, wherein said second anti-cancer therapy is radiotherapy, chemotherapy, gene therapy or surgery.

41. The method of claim 24, wherein said subject has previously received cancer therapy.

42. A method for preventing the development of occult brain metastasis in a subject comprising administering to said subject a composition comprising an immunomodulatory polypeptide and an inflammatory stimulus.